Type 2 Diabetes Clinical Trial
Official title:
Internet Diabetes Self-Management: A Randomized Trial
Diabetes is a growing health problem causing personal suffering, comorbid conditions,
premature death, and high costs to the individual, the health care system and society. Many
of these problems can be prevented or delayed by controlling the disease. This in turn
requires daily self-management by patients.
We will evaluate an Internet based small group Diabetes Self-Management Program. This
program will be adapted from the Chronic Disease Self-Management Program Online, already
developed and currently being evaluated by the investigators. Participants with type 2
diabetes will be randomized to participate in the Internet Program or serve as controls
continuing with usual care. Treatment subjects will participate in a structured 6 week
interactive web-based online class with 20-24 other participants and 2 trained peer
moderators.
If successful, this project will result in a new and effective means of reaching the CDC
objective and more importantly in improving the quality of life and health status of people
with diabetes while reducing health care utilization and thus costs.
Diabetes is a growing health problem causing personal suffering, comorbid conditions,
premature death, and high costs to the individual, the health care system and society. Many
of these problems can be prevented or delayed by controlling the disease. This in turn
requires daily self-management by patients.
The CDC has recognized the importance of self-management by setting a 2010 objective of
having 60% of diabetics receive diabetes education. Unfortunately, many people cannot
receive such education because it is not available or they do not wish to or cannot
participate in small group or one on one education.
The Internet may offer a viable alternative. We will evaluate an Internet based small group
Diabetes Self-Management Program. This program will be adapted from the Chronic Disease
Self-Management Program Online, already developed and currently being evaluated by the
investigators. Participants with type 2 diabetes will be randomized to participate in the
Internet Program or serve as controls continuing with usual care. Treatment subjects will
participate in a structured 6 week interactive web-based online class with 20-24 other
participants and 2 trained peer moderators.
Data will be collected online at baseline, 6 months and 1 year. Outcome measures include
health related quality of life (fatigue, physical discomfort, the symptoms of hypoglycemia
and hyperglycemia, activity limitations, health distress, and self-rated health), metabolic
control (hemoglobin A1c), health care utilization (decreases in outpatient visits to
physicians, increases in the percentage of participants having received an eye examination
in the past year, increases in the number of times a health professional has examined
participants' feet, and decreases in emergency department visits, hospitalizations, and
hospital days), health behaviors (aerobic exercise, communication with physicians, diet,
glucose self-monitoring, and self-examination of the feet), and self-efficacy to manage
diabetes.
If successful, this project will result in a new and effective means of reaching the CDC
objective and more importantly in improving the quality of life and health status of people
with diabetes while reducing health care utilization and thus costs.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |